MGL-3196 Drug Interaction with Rosuvastatin and Simvastatin

Phase 1, open-label, single-arm trial of resmetirom in Nonalcoholic steatohepatitis (NASH), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf)) of Rosuvastatin as affected by MGL-3196 at 72 hours and Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf)) of Simvastatin as affected by MGL-3196 at 24 hours. Started Sep 2015; status: completed.